NO20042172L - Insulinmolekyl med forlenget virkningstid - Google Patents

Insulinmolekyl med forlenget virkningstid

Info

Publication number
NO20042172L
NO20042172L NO20042172A NO20042172A NO20042172L NO 20042172 L NO20042172 L NO 20042172L NO 20042172 A NO20042172 A NO 20042172A NO 20042172 A NO20042172 A NO 20042172A NO 20042172 L NO20042172 L NO 20042172L
Authority
NO
Norway
Prior art keywords
action
extended duration
insulin molecule
insulin
molecule
Prior art date
Application number
NO20042172A
Other languages
English (en)
Norwegian (no)
Inventor
Richard Dennis Dimarchi
Michael Rosario Defelippis
John Michael Beals
Wayne David Kohn
Radmila Micanovic
Sharon Ruth Myers
Lianshan Zhang
Kingman Ng
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20042172L publication Critical patent/NO20042172L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20042172A 2001-12-20 2004-05-25 Insulinmolekyl med forlenget virkningstid NO20042172L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34431001P 2001-12-20 2001-12-20
US41460402P 2002-09-27 2002-09-27
PCT/US2002/037601 WO2003053339A2 (en) 2001-12-20 2002-12-12 Insulin molecule having protracted time action

Publications (1)

Publication Number Publication Date
NO20042172L true NO20042172L (no) 2004-09-17

Family

ID=26993857

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042172A NO20042172L (no) 2001-12-20 2004-05-25 Insulinmolekyl med forlenget virkningstid

Country Status (17)

Country Link
US (1) US20050014679A1 (hr)
EP (1) EP1545460A4 (hr)
JP (1) JP2005519041A (hr)
KR (1) KR20040070237A (hr)
AU (1) AU2002346490A1 (hr)
BR (1) BR0215029A (hr)
CA (1) CA2468100A1 (hr)
CO (1) CO5590884A2 (hr)
CZ (1) CZ2004710A3 (hr)
HR (1) HRP20040551A2 (hr)
HU (1) HUP0700126A2 (hr)
IL (1) IL161848A0 (hr)
MX (1) MXPA04006084A (hr)
NO (1) NO20042172L (hr)
PL (1) PL374949A1 (hr)
SK (1) SK2432004A3 (hr)
WO (1) WO2003053339A2 (hr)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508895A (ja) 2001-08-28 2005-04-07 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１および基礎インスリンの予備混合物
CA2463803A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
BRPI0413276B8 (pt) 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
CA2537636A1 (en) 2003-09-03 2005-03-10 Shmuel Bukshpan Methods and apparatus for rapid crystallization of biomolecules
MXPA06008209A (es) 2004-01-21 2006-08-31 Novo Nordisk As Conjugacion de peptidos mediada por transglutaminasa.
WO2006008238A1 (en) * 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
MX2007003897A (es) * 2004-10-05 2007-05-21 Novo Nordisk As Una formulacion farmaceutica que comprende insulina cristalina e insulina disuelta.
EP2505593A1 (en) 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
WO2008015099A2 (en) * 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
WO2009022005A1 (en) * 2007-08-15 2009-02-19 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
WO2009087082A2 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
CA2713348C (en) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
PL2910570T3 (pl) 2008-03-18 2017-06-30 Novo Nordisk A/S Stabilizowane względem proteaz, acylowane analogi insuliny
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
AU2009240636A1 (en) * 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
KR20120129875A (ko) * 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
KR20110061552A (ko) 2008-07-31 2011-06-09 케이스 웨스턴 리저브 유니버시티 할로겐 안정화된 인슐린
AU2013237740B2 (en) * 2008-07-31 2016-06-02 Case Western Reserve University Insulin analogues containing penta-fluora-phenyalanine at position B24
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
EP2352513B1 (en) 2008-10-30 2016-09-14 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
EA020520B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
MY160219A (en) 2008-12-15 2017-02-28 Zealand Pharma As Glucagon analogues
MX2011006315A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
CN102282166B (zh) 2008-12-15 2015-04-01 西兰制药公司 胰高血糖素类似物
EP2376520B1 (en) 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
CA2747720A1 (en) * 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor
TWI489992B (zh) 2008-12-19 2015-07-01 印地安那大學研究及技術公司 醯胺系胰高血糖素超級家族之胜肽前驅藥物
CA2747195A1 (en) * 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
CN102245624B (zh) * 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
MX2012000564A (es) 2009-07-13 2012-04-11 Zealand Pharma As Analogos de glucagon acilados.
EP2464655B1 (en) * 2009-08-11 2017-02-15 Biocon Limited Chromatographic processes
US8399407B2 (en) 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
JP5119232B2 (ja) * 2009-11-06 2013-01-16 株式会社マルハニチロ食品 プロタミンの定量法
PT2554183T (pt) 2009-11-13 2018-07-09 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
MY159565A (en) 2009-11-13 2017-01-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
MY189079A (en) 2009-12-11 2022-01-25 Univ Case Western Reserve Insulin analogues with chlorinated amino acids
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
CA2802485C (en) 2010-06-16 2019-09-17 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
MX2012014576A (es) 2010-06-24 2013-02-21 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida.
CA2803164C (en) * 2010-06-24 2018-08-21 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
AP2013006671A0 (en) 2010-06-24 2013-01-31 Zealand Pharma As Glucagon analogues
LT2611458T (lt) 2010-08-30 2016-12-27 Sanofi-Aventis Deutschland Gmbh Ave0010 panaudojimas gaminant vaistą, skirtą 2 tipo cukrinio diabeto gydymui
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
WO2012098462A1 (en) 2011-01-20 2012-07-26 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
JP2014509603A (ja) * 2011-03-15 2014-04-21 ノヴォ ノルディスク アー／エス システイン置換を含むヒトインスリン類似体およびヒトインスリン誘導体
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP3053590A1 (fr) 2011-08-10 2016-08-10 Adocia Solution injectable d'au moins une insuline basale
WO2013030160A1 (en) 2011-08-29 2013-03-07 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CN104114183A (zh) 2011-12-20 2014-10-22 印第安纳大学研究及科技有限公司 用于治疗糖尿病的基于ctp的胰岛素类似物
CN107583039A (zh) * 2012-01-09 2018-01-16 阿道恰公司 Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
WO2013110069A1 (en) * 2012-01-20 2013-07-25 Case Western Reserve University Glutamic acid-stabilized insulin analogues
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
WO2013164483A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
DK2875043T3 (en) 2012-07-23 2017-03-27 Zealand Pharma As glucagon
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001896B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
FR3001895B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
MX366636B (es) 2013-10-07 2019-07-17 Novo Nordisk As Nuevo derivado de un análogo de insulina.
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
KR102394515B1 (ko) 2013-10-17 2022-05-09 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
FR3013049B1 (fr) 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
BR112016013832A2 (pt) 2014-01-09 2017-08-08 Sanofi Sa Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico
RU2016132342A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
WO2015104310A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
CN107001441A (zh) 2014-09-24 2017-08-01 印第安纳大学研究及科技有限公司 脂质化的基于酰胺的胰岛素前药
WO2016057529A2 (en) 2014-10-06 2016-04-14 Case Western Reserve University Biphasic single-chain insulin analogues
CA2965732A1 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
CR20170314A (es) 2014-12-12 2017-10-20 Sanofi Aventis Deutschland Formulación de relación fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
PL3283507T3 (pl) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylowany analog glukagonu
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
FR3052072A1 (fr) 2016-06-07 2017-12-08 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
RU2758367C2 (ru) 2016-12-16 2021-10-28 Ново Нордиск А/С Фармацевтические композиции, содержащие инсулин
KR20180002062U (ko) 2016-12-28 2018-07-06 유애자 크리스탈이 구비된 조명커버
FR3070264A1 (fr) 2017-08-24 2019-03-01 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083088B1 (fr) 2018-06-29 2020-10-02 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083089A1 (fr) 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019110625A1 (fr) 2017-12-06 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019110774A1 (fr) 2017-12-07 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
MX2020005913A (es) 2017-12-07 2020-10-19 Adocia Solución inyectable a ph 7 que comprende al menos una insulina basal que tiene un pi de entre 5.8 y 8.5 y un copoliaminoácido con cargas de carboxilato y radicales hidrofóbicos.
WO2019243628A1 (fr) 2018-06-22 2019-12-26 Adocia Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
FR3084585B1 (fr) 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes
US20200179489A1 (en) 2018-12-07 2020-06-11 Adocia Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol
WO2020115334A1 (fr) 2018-12-07 2020-06-11 Adocia Procede de preparation d'une composition stable sous forme d'une solution aqueuse injectable
WO2020245470A1 (fr) 2019-06-07 2020-12-10 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, du liraglutide et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) * 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) * 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3864325A (en) * 1971-11-18 1975-02-04 Nat Res Dev (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
DE3333640A1 (de) * 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
DE3936876A1 (de) * 1989-11-06 1991-05-23 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
NZ245170A (en) * 1991-11-26 1994-07-26 Lilly Co Eli Insulin and proinsulin analogues with arg at b31, b32 and ao and pharmaceutical compositions
DE59409816D1 (de) * 1993-04-27 2001-09-13 Hoechst Ag Amorphe monosphärische Formen von Insulinderivaten
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5491269A (en) * 1994-09-15 1996-02-13 Exxon Production Research Company Method for inhibiting hydrate formation
US5491296A (en) * 1994-12-05 1996-02-13 Holden's Foundation Seeds, Inc. Inbred corn line LH176
WO1999021573A1 (en) * 1997-10-24 1999-05-06 Eli Lilly And Company Fatty acid-acylated insulin analogs
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives

Also Published As

Publication number Publication date
BR0215029A (pt) 2005-12-20
WO2003053339A2 (en) 2003-07-03
AU2002346490A1 (en) 2003-07-09
CZ2004710A3 (cs) 2005-02-16
CO5590884A2 (es) 2005-12-30
SK2432004A3 (sk) 2005-04-01
KR20040070237A (ko) 2004-08-06
PL374949A1 (en) 2005-11-14
HRP20040551A2 (en) 2004-10-31
CA2468100A1 (en) 2003-07-03
HUP0700126A2 (en) 2007-06-28
IL161848A0 (en) 2005-11-20
JP2005519041A (ja) 2005-06-30
EP1545460A4 (en) 2005-11-16
EP1545460A2 (en) 2005-06-29
WO2003053339A3 (en) 2005-04-14
US20050014679A1 (en) 2005-01-20
MXPA04006084A (es) 2005-03-31

Similar Documents

Publication Publication Date Title
NO20042172L (no) Insulinmolekyl med forlenget virkningstid
CY2013029I2 (el) Νεα παραγωγα ινσουλινης
DK1542748T3 (da) Engangssprøjte
DK3210637T3 (da) Infusionssæt
DK1383560T4 (da) Infusionssæt
DE60327864D1 (de) Ballondissektor mit kanüle
DK1687028T3 (da) Immunglobulinpræparater med øget stabilitet
DE60212066D1 (de) Abgabespritze
DK1613694T3 (da) Polyalkenaminer med forbedrede anvendelsesegenskaber
DK1572229T3 (da) Stabilt terapeutisk fibrinogen
DE602004015504D1 (de) Von injektionspräparaten
DE10196460T1 (de) Selbstzerstör-Spritze
DE602004030779D1 (de) Angehen des problems des schrittmachersyndroms
DE502004005095D1 (de) Einspritzdüse
DE10111783B4 (de) Einspritzdüse
DE50211807D1 (de) Schiebernadel
DE502004005873D1 (de) Einspritzdüse
FI20021817A0 (fi) Kanyyli
DE60204435D1 (de) Spritze
DE60206034D1 (de) Spritze
ITVI20020013A1 (it) Siringa per iniezioni
SE0100950D0 (sv) Spruta
FI20012148A0 (fi) Ruisku
DE10295185D2 (de) Anästhesiespritze
UA6623S (uk) Шприц

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application